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Abstract
Human osteoclast formation from mononuclear phagocyte precursors involves interactions between tumor necrosis factor
(TNF) ligand superfamily members and their receptors. Recent evidence indicates that in addition to triggering apoptosis,
the TNF-related apoptosis-inducing ligand (TRAIL) induces osteoclast differentiation. To understand TRAIL-mediated signal
transduction mechanism in osteoclastogenesis, we demonstrated that TRAIL induces osteoclast differentiation via a Tumor
necrosis factor receptor-associated factor 6 (TRAF-6)-dependent signaling pathway. TRAIL-induced osteoclast differentiation
was significantly inhibited by treatment with TRAF-6 siRNA and TRAF6 decoy peptides in both human monocytes and
murine RAW264.7 macrophage cell lines, as evaluated in terms of tartrate-resistant acid phosphatase (TRAP)-positive
multinucleated cells and bone resorption activity. Moreover, TRAIL-induced osteoclast differentiation was also abolished in
TRAF6 knockout bone marrow macrophages. In addition to induction of NFATc1, treatment of TRAIL also induced
ubiquitination of TRAF6 in osteoclast differentiation. Thus, our data demonstrate that TRAIL induces osteoclastic
differentiation via a TRAF-6 dependent signaling pathway. This study suggests TRAF6-dependent signaling may be a central
pathway in osteoclast differentiation, and that TNF superfamily molecules other than RANKL may modify RANK signaling by
interaction with TRAF6-associated signaling.
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Introduction
Osteoclasts are multinucleated cells, derived from precursors of
monocyte/macrophage lineages. Osteoclasts are involved in bone
absorption and remodeling. It is already known that normal
differentiation of osteoclasts requires TNF family receptors, such
as the receptor activator of nuclear factor-kB (RANK)
[1,2,3,4,5]. It is likely that the RANK/RANK ligand
(RANKL)/osteoprotegerin (OPG) system system is the central
and primary regulator of bone remodeling; however, it is clear
that this is not the only mechanism involved. Many of the
cytokines and growth factors implicated in inflammatory
processes in rheumatic diseases have also been demonstrated to
impact osteoclast differentiation and function either directly, by
acting on cells of the osteoclast-lineage, or indirectly, by acting
on other cell types to modulate expression of the key
osteoclastogenic factor, RANKL, and/or its inhibitor, OPG
[6,7,8,9,10]. In addition to RANKL, recent studies have
demonstrated there are several TNF family molecules which
promote osteoclast differentiation, including TNF [11], decoy
receptor 3 (DcR3) [12], FasL [13] and TRAIL [14]; indicating
that activated T cells and inflammatory response can remodel
bone homeostasis via these effector molecules. TRAIL, a
member of the TNF ligand superfamily, induces apoptosis in
diverse tumor cell lines [15], and its expression is upregulated in
activated T cells. In our previous studies, we have demonstrated
that in addition to triggering apoptosis, TRAIL induces osteoclast
differentiation in mononuclear phagocyte precursors [14]. Our
results indicate that this mechanism may be implicated in
osteoimmunology in immune response-associated bone absorp-
tion. However, the mechanism and signaling pathways of
TRAIL-induced osteoclast differentiation is still not clear.
Ligands for these receptors plus unidentified serum or cell-
presented factor(s) are necessary for in vitro differentiation,
indicating the involvement of signaling pathways possibly via
an immune-like tyrosine kinase acceptor molecule. RANK
provokes biochemical signaling via the recruitment of intracel-
lular tumor necrosis factor receptor-associated factors (TRAFs)
after ligand binding and receptor oligomerization. Accumulating
evidence from various laboratories indicates TRAFs, most
importantly TRAF6, is the key to understanding how RANKL
links cytoplasmic signaling to the nuclear transcriptional program
[16,17,18,19,20]. However, the signaling pathways for TRAIL-
induced osteoclast differentiation and whether TRAF6-depen-
dent signaling is essential for this effect is still not clear. To
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38048understand the TRAIL-mediated signal transduction mechanism
in osteoclastogenesis, we study role of TRAF6 –dependent
signaling in TRAIL-induced osteoclast differentiation and bone
resorption. Our results indicate that TRAF6 is essential for
TRAIL-induced osteoclast differentiation and bone resorption
activity. This study suggests TRAF6-dependent signaling may be
a central pathway in osteoclast differentiation, and TNFs other
than RANKL may modify RANK signaling by interaction with
TRAF6-associated signaling.
Materials and Methods
Cell Lines
We used human peripheral blood mononuclear cells (PBMCs)
and the RAW264.7 murine monocytic/macrophagic cell line as
model systems of osteoclastogenesis. Both cell types differentiate
into osteoclast-like cells in the presence of RANKL plus M-CSF
[21,22]. RAW264.7 cells, which were derived from a tumor
induced by the Abelson murine leukemia virus, were purchased
from American Type Culture Collection (ATCC; Rockville, MD).
Cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal calf serum (FCS), 2 nM L-
glutamine, and 100 U/ml penicillin/streptomycin. For osteoclast
culture, RAW cells were seeded in a 96-well plate at a density of
2610
3 cells/well and cultured for 5 days in the presence of 25 ng/
ml M-CSF and 50 ng/ml RANKL, as the positive control, or
0.5 mg/ml TRAIL. The medium was replaced every 3 days.
Human PBMCs from healthy donors were separated by gradient
centrifugation with Ficoll-Hypaque and were re-suspended in a-
MEM supplemented with 10% heat-inactivated FBS. PBMCs
were then plated in 96-well plates at 1610
6 cells/well and
incubated in the absence or presence of 500 ng/ml TRAIL for 30
days. The medium was replaced every 3 days.
Transfection of TRAF6 or TRAIL-R siRNAs
To test the role of TRAF6 or TRAIL-R in TRAIL-induced
osteoclastogenesis, RAW 264.7 cells were transfected with a pool of
4 specific siRNAs (Thermo Scientific, Dharmacon, CO) or
nonspecific control siRNA, and then treated with TRAIL. The
ON-TARGET plus SMART pool TRAF6 siRNA target sequences
were GCACAGCAGUGUAACGGGA, GGACAAGGUUGCC-
GAAAUG, GAGAACAGAUGCCUAAUCA, GCUCAAUC-
GUUUAAUAAGA. The ON-TARGET plus SMART pool
TRAIL-R siRNA target sequences were UAAGGAAGAUAAA-
GUCGUA, UAAGCUAGGCCUCUGGAUA, GAAACCC-
GAUGCAACAUAA, GAGCAUGGAGGCAAUGGUU.
The transfection of siRNA into human macrophages and RAW
264.7 cells was performed by electroporation. In brief, RAW 264.7
cells (5610
6 cells) were gently mixed with siRNA (2nmole) in
electroporation buffer (0.8% glucose, 20% FBS in antibiotics-free
RPMI), transferred to an electroporation cuvette, and electropo-
rated using the GenepluserII device. The expression of TRAIL-R
was detected with anti-TRAIL-R mAb (Chemicon and Upstate,
Billerica, MA).
Osteoclast Differentiation
For osteoclastic differentiation, cells were cultured in the
presence of either 50 ng/mL human M-CSF (for PBMCs; R&D
Systems, Minneapolis, MN) or murine M-CSF (for RAW264.7;
R&D Systems), and 50 ng/mL human RANKL (for PBMCs,
R&D Systems) or murine RANKL (for RAW264.7, R&D
Systems), or recombinant TRAIL proteins purified from an
Escherichia coli expression system as previously described [23]. To
remove the endotoxin, the purified recombinant TRAIL proteins
were further treated with Detoxi-GelTM Endotoxin Removing
Gel (Pierce, Rockford, IL) to remove the lipopolysaccharide (LPS)
during purification. The absence of endotoxin contamination in
the recombinant TRAIL preparation (,0.1 endotoxin units/mL)
was assessed by a Limulus Amoebocyte Lysate (LAL) assay
(BioWhittaker, Walkersville, MD).
The TRAF6 inhibitory peptide, T6PD (DRQI-
KIWFQNRRMKWKKRKIPTEDEY; IMGENEX, San Diego,
CA), which was shown to specifically target TRAF6 and inhibit
RANKL-mediated signaling and osteoclast differentiation [24],
was used to examine its effects on TRAIL-mediated osteoclast
differentiation in RAW macrophages. For some experiments, we
also used recombinant osteoprotegerin (OPG) Fc fusion protein
(R&D System Inc, Minneapoli, MN) and anti-TRAIL-R blocking
antibody (R&D System Inc, Minneapolis, MN) to block the
interaction between TRAIL and TRAIL receptor in osteoclast
differentiation.
TRAP Staining
Osteoclast formation was measured by quantifying cells
positively stained with TRAP (Acid Phosphatase Kit 387-A;
Sigma-Aldrich, St. Louis, MO). Briefly, specimens were fixed for
30 s and then stained with naphthol AS-BI phosphate and a
tartrate solution for 1 h at 37uC, followed by counterstaining with
a hematoxylin solution. Osteoclasts were determined to be TRAP-
positive staining multinuclear (.3 nuclei) cells using light
microscopy. TRAP-positive multinuclear cells with three or more
nuclei were regarded as osteoclasts and counted under an
inverted-phase contrast microscope. The total number of TRAP-
positive cells and the number of nuclei per TRAP-positive cells in
each well were counted. The morphological features of osteoclasts
were also photographed.
Bone Resorption Assay
In order to confirm the bone resorption ability by differentiated
osteoclasts, human monocytes were plated onto a 24-well plates
coated with artificial bone slides (calcium phosphate apatite plate;
OAAS, Osteogenic Core Technologies, Irvine, CA) under the
same culture conditions as described above. After a 30- day
culture, each well was washed with saline, and a solution of 5%
sodium hypochlorite was left in the well for 5 min in order to
detach the cells. The number of resorption pits and bone
resorptive area in each well was counted under a microscope.
The pits were also photographed.
Flow Cytometric Analysis
For the flow cytometric analysis, adherent cells were harvested
from culture plates by gentle scraping on ice. Surface cell staining
was performed at 4uC for 40 min by incubating 3 610
5 cells in
200 mL phosphate-buffered saline (PBS; containing 1% bovine
serum albumin (BSA) and 5% human plasma) with the indicated
antibodies (Abs). Expression of monocytic/macrophagic markers
was documented using phycoerythrin (PE)-conjugated anti-CD14
(Immunotech, Marseille, France) and anti-CD36 monoclonal Abs
(mAbs; BD Pharmingen, San Diego, CA), and fluorescein
isothiocyanate (FITC)-conjugated anti-CD64 mAb (Immunotech).
Nonspecific fluorescence was assessed by incubation with irrele-
vant isotype-matched conjugated mAbs. Flow cytometric analyses
were performed by FACScan (Becton Dickinson, San Diego, CA).
Activation of NFATc1
For detecting activation of NFATc1, the RAW264.7 cells were
treated with TRAIL (500 ng/ml), M-CSF (20 ng/ml) and
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After stimulation, cells lysates of the nuclear fraction were
prepared. Nuclear and cytosolic proteins were separated upon
resuspension of the pelleted cells (10
6)i n3 0ml hypotonic lysis
buffer [10 mM Tris-HCl (pH 7.4), 10 mM NaCl, 3 mM MgCl2,
and 0.5% NP-40] by gentle pipetting, then incubation on ice for
5 min. The homogenate was centrifuged at 6000 rpm for 5 min at
4uC. The supernatant representing the cytosolic fraction was
collected then stored at –80uC, and the pellet containing cell nuclei
was lysed in 30 ml RIPA lysis buffer. The nuclear extract
(supernatant) was retained after centrifugation at 13,000 g for
5 min at 4uC for subsequent Western blotting with anti-NFATc1
(Thermo Scientific, Rockford, IL) and anti-HDAC antibodies (Cell
signaling, Danvers, MA).
Ubiquitination of TRAF6
For assaying ubiquitination of TRAF6, we transfected the
ubiquitin plasmid into RAW 264.7 cells, and the cells were treated
with recombinant TRAIL. The whole-cell lysate was prepared
24 h after treatment with TRAIL. The cell lysates were then
Immunoprecipitated with an anti-TRAF6 polyclonal antibody
(Santa Cruz Biotechnology, Santa Cruz, CA), and analyzed by
SDS-PAGE and Western blotting transferred to nitrocellulose
membranes. TRAF6 ubiquitination was detected with an anti-
ubiquitin antibody (Santa Cruz Biotechnology, Santa Cruz, CA)
and anti-TRAF6 mAb (Abcam, Cambridge, UK). The ubiquitin
plasmid was kindly provided from Dr. Ming-Zong Lai (Academia
sinica, Taiwan).
Statistical Analysis
Data are expressed as the mean6SD from at least three
experiments. Student’s t-test was used to assess the statistical
significance of the differences, and a p value of ,0.05 was
considered statistically significant.
Results
TRAIL Induced Osteoclast Differentiation in Human
PBMCs and Murine RAW264.7 Cells is TRAF6 Dependent
To determine role of TRAF6 –dependent signaling in TRAIL-
induced osteoclast differentiation, we first investigated the
influence of TRAF6 in TRAIL-induced osteoclast differentiation
in human preosteoclastic precursors. For this purpose, human
PBMCs were allowed to adhere for 3,5 days. The adherent
PBMCs were positive for the monocytic/macrophagic markers
CD14, CD36, and CD64 at this time point (data not shown).
Monocyte precursors can differentiate into osteoclast-like cells in
the presence of RANKL (100 ng/ml) and M-CSF (50 ng/ml) or
TRAIL (500 ng/ml). This differentiation was verified not only by
the appearance of multinuclear cells but also by the positive
staining with TRAP. The formation of large, multinucleated
TRAP
+ cells was observed, characterized by the appearance of
TRAP-positive giant multinucleated cells with more than three
nuclei. In our previous study, TRAIL in this does range did not
induce apoptosis; instead, TRAIL induced osteoclast differentia-
tion in preosteoclastic precursors [14] (Figure S1). We then
examined whether the TRAIL-induced osteoclast differentiation
activity is dependent on TRAF6 signaling pathway after TRAIL
engagement. The monocyte precursors were treated with TRAIL
(500 ng/ml) as well as M-CSF (50 ng/ml) and RANKL (100 ng/
ml) in the presence or absence of TRAF6 siRNA, TRAF6 decoy
peptide (T6DP) or osteoprotegerin (OPG). In addition to being an
inhibitor of RANKL, OPG is also a decoy receptor for the
cytotoxic ligand TRAIL [25]. OPG can bind to TRAIL to
neutralize the osteoclast differentiation effects induced by TRAIL
[14]. In Figure 1, our results demonstrated that both RANKL-
and TRAIL-induced osteoclast differentiation ability was signifi-
cantly inhibited after silencing the expression of TRAF6 by using
TRAF6 siRNA, indicating that TRAIL-induced osteoclast differ-
entiation activity is dependent on TRAF6 (Figure 1). Both
RANKL- and TRAIL-induced osteoclast differentiation was also
significantly reduced when treated with OPG.
For further demonstration of the role of TRAF6 in TRAIL-
mediated signaling in osteoclast differentiation, a cell-permeable
TRAF6 decoy peptide (T6DP), which was shown to specifically
target TRAF6 and inhibit RANKL-mediated signaling and
osteoclast differentiation [24], was used to examine its effects on
TRAIL-mediated osteoclast differentiation in human macrophag-
es. The results in Figure 1 demonstrated that TRAIL-induced
osteoclast differentiation was significantly reduced after adding the
TRAF6 decoy peptide, T6DP into the culture, indicating that
TRAIL-induced osteoclast differentiation activity is dependent on
TRAF6 signaling pathway.
TRAIL-induced Osteoclast Differentiation and Bone
Resorption Activity is Dependent on TRAF6
To further determine whether TRAF6 signaling pathway is
essential for TRAIL-induced osteoclast differentiation and bone
resorption activity, we performed functional assays for identifica-
tion of osteoclast differentiation in an in vitro culture system. Using
commercial calcium phosphate apatite as a resorption substrate,
pit formation caused by TRAIL-treated human macrophages was
compared to cultures of cells in the presence or absence of TRAF6
siRNA and the TRAF6 decoy peptide, T6DP (Figure 2). Lacunar
resorption was observed in human macrophages treated with
TRAIL on calcium phosphate apatite plates; however, the bone
resoprtion activity was significantly reduced after treatment with
TRAF6 siRNA or the TRAF6 decoy peptide, T6DP (Figure 2).
Taken together, our results clearly demonstrated that TRAF6 is
essential for TRAIL-induced osteoclast differentiation and bone
resorption activity.
TRAIL-induced Activation of MAP Kinases is Dependent
on TRAF6
Three members of MAPKs, ERK, p38 MAPK, and JNK, have
been implicated in the mediation of cytokine-regulated osteoclas-
togenesis [26,27,28]. To elucidate the signaling pathways under-
lying TRAIL’s action, we examined the activation of MAPKs in
Figure 1. TRAIL induced osteoclast differentiation is dependent on TRAF6. (A) Human peripheral blood mononuclear cells (PBMCs) were
plated in 96-well plates at 1.5 610
5 cells/well, and the next day the adherent monocytes were treated with TRAIL (500 ng/ml) as well as M-CSF
(50 ng/ml) and RANKL (100 ng/ml) in the presence or absence of TRAF6 siRNA, control siRNA (Crtl siRNA), TRAF6 decoy peptide (T6DP), control
peptide (Crtl peptide), or osteoprotegerin (OPG) as indicated in the figure for 30 days. The transfection of siRNAs into human macrophages cells was
performed by electroporation. The TRAF6 inhibitory peptide, T6PD and its control peptide were used to examine its effects on TRAIL-mediated
osteoclast differentiation. After incubation, cells were subjected to the TRAP assay. Cell morphology was examined by light microscopy, and the
number of TRAP-positive multinuclear cells was quantified. The bar in each figure represents 100 mM. (B). TRAIL-induced formation of osteoclast-like
multinucleated cells from human monocytes. Data in (B) represent the mean6SD from three to six independent experiments. *p , 0.05, **p , 0.005.
doi:10.1371/journal.pone.0038048.g001
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presence or absence of TRAF6 siRNA by immunoblotting. As
shown in Figure 3, expression of TRAF6 was upregulated when
treated with TRAIL or RANKL plus M-CSF in RAW264.7
macrophages. TRAIL induced the phosphorylation of p38
MAPK, JNK, and ERK in osteoclast precursors, and silencing
of TRAF6 by treatment of TRAF6 siRNA inhibited the TRAIL-
induced phosphorylation of p38 MAPK, JNK and ERK in
RAW264.7 macrophages (Figure 3). These results suggest that
TRAF6 is critical in TRAIL-induced activation of MAP kinases in
osteoclastogenesis signaling.
TRAIL-induced Activation of NFATc1 in
Osteoclastogenesis is TRAF6-dependent
RANKL induces activation of the TRAF6 and c-Fos pathways,
which lead to the osteoclast-specific event of autoamplification of
nuclear factor of activated T cells (NFAT)c1, the master
transcription factor for osteoclast differentiation [29,30,31].
However, it is not clear whether TRAIL induces activation of
NFATc1 in osteoclastogenesis; or if TRAF6 is essential for
activation of NFATc1 in TRAIL-induced osteoclast differentia-
tion. For further support TRAIL induces osteoclast differentiation
through direct engagement with TRAIL receptor and to transduce
signaling via TRAF6, we used the TRAIL receptor (TRAIL-R)
siRNA to knock down the expression of TRAIL-R and also used
the anti-TRAIL-R antagonist Ab (R&D System, Inc., Minneap-
olis, MN) to neutralize the interaction between TRAIL and its
receptor. The results in Figure 4 demonstrated that TRAIL-
induced activation of NFATc1 was significantly inhibited by
transfection of TRAF6 siRNA, TRAIL-R siRNA, or treatment
with anti-TRAIL-R antagonist Ab, indicating that TRAIL-
induced NFATc1 activation and osteoclast differentiation activity
is dependent on TRAF6 associated signaling (Figure 4).
In addition,TRAF6 is a RING-dependent ubiquitin (Ub) ligase
that in conjunction with Ubc13/Uev1A catalyzes its own auto-
ubiquitination via Lys63-linked poly-Ub chains [32]. It has been
demonstrated that TRAF6 RING-dependent Ub ligase activity
and TRAF6 auto-ubiquitination is critical for RANKL signaling
and osteoclast differentiation [32,33,34,35]. It is not clear whether
TRAIL induces activation of TRAF6 auto-ubiquitination and its
role in osteoclastogenesis. In Figure 4, our results demonstrated
that in addition to induction of NFATc1, treatment of TRAIL in
RAW264.7 cells also induced ubiquitination of TRAF6, and
which was significantly inhibited by transfection of TRAF6
siRNA, TRAIL-R siRNA, or treatment with anti-TRAIL-R
antagonist Ab, indicating that TRAIL-induced ubiquitination of
TRAF6 is involved in NFATc1 activation and osteoclast
differentiation, and the ubiquitination is TRAF6-dependent.
Figure 2. TRAIL-induced osteoclast bone resorption activity is TRAF6-dependent. (A). Human monocytes were plated on an artificial bone
matrix slide (calcium phosphate apatite-coated plate; OAAS) and were cultured with TRAIL (500 ng/ml) as well as M-CSF (50 ng/ml) and RANKL
(100 ng/ml) in the presence or absence of TRAF6 siRNA, control siRNA (Crtl siRNA), TRAF6 decoy peptide (T6DP), control peptide (Crtl peptide), or
osteoprotegerin (OPG) as indicated. Cells were detached after 30 days of culture. The number of resorption pits and resorptive area in each well was
observed and counted using a microscope. (B). The resorption pits were photographed and the resorptive area in each well was counted. Data in (B)
represent the mean6SD from five independent experiments. *p , 0.05, **p , 0.005.
doi:10.1371/journal.pone.0038048.g002
Figure 3. TRAIL induces activation of MAP Kinases is dependent on TRAF6. RAW264.7 cells were treated with TRAIL (500 ng/ml), M-CSF
(20 ng/ml) and RANKL (50 ng/ml) in the presence or absence of TRAF6 siRNA. After stimulation, cells were solubilized, and cell lysates were subjected
to Western blot analysis of TRAF6, p38 MAPK, JNK, and ERK1/2. The trace shown in the top panel for each group indicates the immunoreactivity of
the phosphorylated kinase. The same membrane was then stripped and reprobed with the kinase antibody recognizing the total protein level of
kinase (bottom panel). The results are representative of five separate experiments.
doi:10.1371/journal.pone.0038048.g003
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Abolished in TRAF6 Knock Out Bone Marrow
Macrophages
For further determination role of TRAF6-dependent signaling
in TRAIL-induced osteoclast differentiation, we isolated bone
marrow derived macrophage from TRAF6 knockout mice, and
assayed the ability of osteoclast differentiation induced by TRAIL.
The results in Figure 5 demonstrated that the TRAIL- and
RANKL-induced osteoclast differentiation activity was completely
abolished in TRAF6 knockout bone marrow macrophages. Our
results indicated TRAF6 is essential for TRAIL-induced osteoclast
differentiation.
Discussion
In this study, we demonstrated that TRAIL induced
monocyte/macrophage lineage precursor cells to differentiate
into osteoclast-like cells, and TRAIL induces osteoclastic
differentiation via a TRAF-6 dependent signaling pathway.
Osteoclast formation from mononuclear phagocyte precursors
involves interactions between TNF ligand superfamily members
and their receptors [2,3,4,6,7]. However, the signaling pathways
and whether TRAF6-dependent signaling is essential for
TRAIL-induced osteoclast differentiation is still not clear. Our
data is the first to demonstrate TRAF6 is essential for TRAIL
induces osteoclast differentiation and bone resorption activity. A
model for TRAIL-induced activation of the TRAF6 associated
signaling pathway in osteolcast differentiation is shown in
Figure 6. Upon receptor engagement, in addition to transduce
apoptosis signaling pathway, TRAIL induces activation of
TRAF6 via a distinct signaling pathway. TRAF6 is the key
molecule linking cytoplasmic signaling to the nuclear transcrip-
tional program in osteoclast differentiation and bone resorption.
TNF superfamily molecules other than RANKL may modify
RANK signaling by interaction with TRAF6-associated signal-
ing. This will provide new insights into the molecular
Figure 4. TRAIL-induced activation of NFATc1 in osteoclast differentiation is dependent on TRAF6. (A). RAW264.7 cells were treated
with TRAIL, M-CSF (20 ng/ml) and RANKL (50 ng/ml) in the presence or absence of TRAF6 siRNA, TRAIL receptor (TRAIL-R) siRNA, anti-TRAIL-R
antagonist Ab, or OPG as indicated in the figure. After stimulation, cells lysates of the nuclear fraction were prepared, and immunoblotted with anti-
NFATc1 and anti-HDAC antibodies. The results are representative of three separate experiments. (B).TRAF6 is ubiquitinated after TRAIL stimulation.
Ubiquitin transfected RAW 264.7 cells were treated with TRAIL in the presence or absence of TRAF6 siRNA, TRAIL-R siRNA, anti-TRAIL-R antagonist Ab,
or OPG as indicated in the figure. The cell lyses were immunoprecipitated with anti-TRAF6 mAb. Bound proteins were subjected to SDS–PAGE and
immunoblotted with anti-Ubiquitin mAb, and then the membrane was stripped and reprobed with anti-TRAF6 mAb. The results are representative of
three separate experiments.
doi:10.1371/journal.pone.0038048.g004
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immune response associated with bone absorption.
The present observation that TRAIL can enhance osteoclast
differentiation from monocyte lineages through activation of
TRAF6 and NFATc1 further strengthens the significance of
Figure 5. TRAIL-induced osteoclast differentiation was abolished in TRAF6 knock out bone marrow-derived macrophages. (A) Bone
marrow-derived macrophages isolated from TRAF6 knock out (TRAF6 KO) mice were treated with TRAIL (500 ng/ml) or RANKL (100 ng/ml) with M-
CSF (200 ng/ml) for 7 days. After incubation, cells were subjected to the TRAP assay. Cell morphology was examined by light microscopy, and the
number of TRAP-positive multinuclear cells was quantified. (B). TRAIL-induced formation of osteoclast-like multinucleated cells from bone marrow-
derived macrophages isolated from wild type and TRAF6 KO mice. Data in (B) represent the mean6SD from three independent experiments. *p ,
0.005.
doi:10.1371/journal.pone.0038048.g005
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PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e38048distinct signaling to modulate cell function in addition to
inducing apoptosis. Our results further indicate that TRAIL
induces osteoclast differentiation via signaling pathways depen-
dent on TRAF6. TRAF6 is perhaps the most important
RANK-associated molecule regulating osteoclast formation and
function. The significance of TRAF6 in the maintenance of
normal bone architecture was demonstrated in TRAF6 knock-
out mice, which displayed a defect in NF-kB signaling and
consequently developed osteopetrosis [16,17]. Although their
ultimate consequences are often transcriptional, the osteoclast-
regulating signals directly mediated by TRAF6, identified to
date, occur in the cytoplasm. These signals include activation of
NF-kB by a process of ubiquitination in which TRAF6
functions as an E3 ligase [36]. Our results support the notion
that TRAF6 is the key molecule linking cytoplasmic signaling to
the nuclear transcriptional program in osteoclast differentiation
and bone resorption. This study suggests that TRAF6-depen-
dent signaling may be a central pathway in osteoclast
differentiation, and TNFs other than RANKL may modify
RANK signaling by interaction with TRAF6-associated signal-
ing.
RANKL induces activation of the TRAF6 and c-Fos pathways,
which lead to the osteoclast-specific event, that is, autoamplifica-
tion of NFATc1, the master transcription factor for osteoclast
differentiation [29,30,31]. Our results demonstrated that in
TRAIL induces activation of NFATc1 in osteoclast differentiation,
and knockdown of TRAF6 abolished the NFATc1 activity
induced by TRAIL (Figure 4), indicating that TRAIL- induced
NFATc1activation and osteoclast differentiation activity is depen-
dent on TRAF6 associated signaling.
Figure 6. A model for TRAIL-induced activation of the TRAF6 associated signaling pathway in osteolcast differentiation. Upon
receptor engagement, in addition to transduce apoptosis signaling pathway, TRAIL induces activation of TRAF6, at least in part through the E3
ubiquitin ligase activity of the TRAF6 RING finger domain via a distinct signaling pathway. In osteoclast precursors, TRAIL is not able to induce
sufficient amount of signals to activate the downstream apoptosis signaling to induce apoptosis; instead, TRAIL induces signaling to activate TRAF6
after receptor engagement. TRAF6 is the key molecule linking cytoplasmic signaling to the nuclear transcriptional program in osteoclast
differentiation and bone resorption. These signals include activation of NF-kB by a process of ubiquitination in which TRAF6 functions as an E3 ligase
[36] and recruitment of the TAB1-TAB2-TAK1 complex, which lead to the osteoclast-specific event, that is, autoamplification of NFATc1, the master
transcription factor for osteoclast differentiation [29,30,31].
doi:10.1371/journal.pone.0038048.g006
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PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e38048In conclusion, our results demonstrated that TRAF6 is essential
for TRAIL induced osteoclast differentiation and bone resorption
activity. Our study supports the notion that TNF superfamily
molecules other than RANKL may modify RANK signaling by
interaction with TRAF6-associated signaling. The novel function
of TRAF6 in TRAIL-mediated osteoclastogenesis demonstrated in
this study indicates a new role for TRAIL in regulating
osteoclastogenesis, and will be helpful in developing better
strategies for treating inflammation-induced bone resorption in
the future.
Supporting Information
Figure S1 TRAIL-induced formation of osteoclast-like
multinucleated cells from human monocytes. (A). Human
peripheral blood mononuclear cells (PBMCs) were plated in 96-
well plates at 1.5610
5 cells/well, and the next day the adherent
monocytes were treated with TRAIL at the concentrations
indicated. After incubation, cells were subjected to the TRAP
assay. Cell morphology was examined by light microscopy. (B).
The adherent human monocytes were treated with TRAIL at the
concentrations indicated, and were subjected to dell death assay.
The cell death was analyzed with MTT cell viability assay. The
Etoposide serves as a positive control for cell death.
(TIF)
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